Back to top

Image: Bigstock

Pacific Biosciences of California Inc.

Read MoreHide Full Article

In the past six months, shares of Pacific Biosciences underperformed the broader industry trend. Pacific Biosciences exhibited a promising fourth quarter of 2016, squarely beating the Zacks Consensus Estimate. Solid contribution from the Instrument and Consumable revenue platforms is a significant positive. We are also upbeat about the higher margin sales of the SequelTM System. However, headwinds related to the limited availability of SMRT cells (Single Molecule, Real-Time) for the Sequel system, flat contractual revenues in the last reported quarter and higher non-cash operating expenses are expected to mar the prospects over the long haul. Further more, the company expects the first-quarter of 2017 revenues to be lower than the fourth quarter, courtesy of the decline in contractual revenues.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Pacific Biosciences of California, Inc. (PACB) - free report >>

Published in